分析脐带血TNF抑制剂水平验证EULAR妊娠期用药推荐
该研究基于111例活动性类风湿关节炎患者的脐带血和母血样本,分析不同TNF抑制剂(TNFi)的脐带血浓度。结果显示遵循EULAR推荐的停药时间点后,脐带血中TNFi缺失或处于低水平。
要点
- 遵循EULAR停药推荐后脐带血TNFi缺失或低水平
- 培塞利珠单抗脐带血检出率5.9%,依那西普未检出
- 阿达木单抗和英夫利西单抗脐带血检出率较高
核心结论
- 遵循EULAR妊娠期TNFi使用推荐可导致脐带血中TNFi缺失或低水平。
研究设计与样本
- 研究纳入111例来自活动性类风湿关节炎孕前咨询研究的患者,按EULAR推荐时间点停用TNFi,采集母血和脐带血分析TNFi浓度。
主要发现
- 培塞利珠单抗中位停药孕周37.0周,脐带血检出率5.9%,中位浓度0.3 µg/mL(IQR 0.2-1.3),中位脐带血/母血浓度比0.010。
- 依那西普中位停药孕周25.0周,脐带血未检出。
- 阿达木单抗中位停药孕周19.0周,脐带血检出率48.0%,中位浓度0.5 µg/mL(IQR 0.2-0.7),中位浓度比0.062(IQR 0.018-0.15)。
- 英夫利西单抗中位停药孕周18.4周,脐带血检出率57.1%,中位浓度0.4 µg/mL(IQR 0.1-1.2),中位浓度比0.012(IQR 0.006-0.081)。
临床怎么用
- 临床可参考EULAR推荐的停药时间点管理妊娠期RA患者的TNFi使用,以降低脐带血TNFi暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To minimise placental transfer of tumour necrosis factor inhibitors (TNFi), the European League Against Rheumatism (EULAR) created points to consider (PtC) for the use of TNFi during pregnancy. We are the first to validate the EULAR-PtC by analysing TNFi concentrations in cord blood. METHODS: Patients were derived from the Preconceptional Counselling in Active Rheumatoid Arthritis Study. TNFi was stopped at the time points recommended by the EULAR. Maternal blood and cord blood were collected and analysed for the concentration of TNFi. RESULTS: 111 patients were eligible for the analysis. Median stop time points were gestational age (GA) 37.0 weeks for certolizumab pegol, GA 25.0 weeks for etanercept, GA 19.0 weeks for adalimumab and GA 18.4 weeks for infliximab. Certolizumab pegol (n=68) was detectable in 5.9% of cord blood samples, with a median concentration of 0.3 µg/mL (IQR: 0.2-1.3) and a median cord/maternal concentration ratio of 0.010. Etanercept (n=30) was not detected in any cord blood samples. Adalimumab (n=25) was detectable in 48.0% of cord blood samples, with a median concentration of 0.5 µg/mL (IQR: 0.2-0.7) and a median concentration ratio of 0.062 (IQR: 0.018-0.15). Infliximab (n=14) was detectable in 57.1% of cord blood samples, with a median concentration of 0.4 µg/mL (IQR: 0.1-1.2) and a median concentration ratio of 0.012 (IQR: 0.006-0.081). CONCLUSION: Compliance with the EULAR-PtC results in absence or low levels of TNFi in cord blood.
引用
- Ghalandari N, Kemper E, Crijns IH, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2021. PMID: 34493490. doi:10.1136/annrheumdis-2021-221036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。